Comment on "Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial".

Yusuf SM, Sattar A, Sharabu R

Open source

DOI
10.1007/s00345-026-06651-3
Published
2026 Aug 1
Container
World journal of urology
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00345-026-06651-3,
  title = {Comment on "Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial".},
  author = {Yusuf SM and Sattar A and Sharabu R},
  year = {2026},
  journal = {World journal of urology},
  doi = {10.1007/s00345-026-06651-3},
  url = {https://doi.org/10.1007/s00345-026-06651-3}
}

RIS

TY  - JOUR
TI  - Comment on "Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial".
AU  - Yusuf SM
AU  - Sattar A
AU  - Sharabu R
PY  - 2026
JO  - World journal of urology
DO  - 10.1007/s00345-026-06651-3
UR  - https://doi.org/10.1007/s00345-026-06651-3
ER  - 

APA

SM, Y., A, S., & R, S. (2026). Comment on "Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial".. World journal of urology. https://doi.org/10.1007/s00345-026-06651-3

Source records